Reactions in Canine Skin with Human Leukocyte Lysates

Tomar, Russell H.; Terzian, James A.

doi:10.3181/00379727-156-39915

Cited by 8 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several reports have suggested that the beneficial effects of stem-based cell therapy are due to paracrine effects such as growth factors or cytokines from the cells, and not due to the differentiation ability of the stem cells themselves [ 37 ]. In this regard, several studies have shown that different hematopoietic cells, including BM cells [ 17 , 25 ], platelets [ 18 ], and peripheral blood leukocytes [ 19 ] are rich in growth factors and cytokines, in particular insulin-like growth factor 1 (IGF-1) and vascular endothelial growth factor (VEGF). Given that these factors are of great beneficial therapeutic potential in different disease settings, the above-mentioned studies would indicate that BML may induce stem cell mobilization and the release of myeloid cells in particular in the leukopenic microenvironment [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Beneficial Modulatory Effects of Treatment With Bone Marrow Lysate on Hematopoietic Stem Cells and Myeloid Cells in Tumor-Bearing Mice

Salem¹,

El-Bakry²,

Moubark³

et al. 2022

Br J Biomed Sci

View full text Add to dashboard Cite

Introduction:Leukopenia is one of the major side effects of myelosuppressive chemotherapy such as cyclophosphamide (CTX). We and others have used CTX either alone or in combination with G-CSF for the mobilization of hematopoietic stem cells (HSCs). This mobilization can induce expansion of myeloid cells with immunosuppressive phenotype. In this pilot study, we aimed to test whether bone marrow lysate (BML)/CTX, a rich source of growth factors, can lower the expansion of myeloid cells with immunosuppressive phenotypes in tumor-bearing mice without interfering with the anti-tumor effects of CTX or with the mobilization of HSCs.Methods:Female CD1 mice were treated on day 0 with an i.p. injection of Ehrlich ascites carcinoma (EAC). On day 7, the mice were i.p. injected with CTX followed by s.c. injection of G-CSF for 5 consecutive days, single s.c. injection of BML/PBS or BML/CTX or single i.v. injection of BMC/PBS or BMC/CTX.Results:Treatment of EAC-bearing mice with BML/PBS or BML/CTX did not interfere with the anti-tumor effect of CTX. EAC increased the numbers of immature polymorphonuclear cells (iPMN; neutrophils) in both blood and spleen. Treatment of EAC-bearing mice with CTX further increased the numbers of these cells, which were decreased upon treatment with BML/CTX. Treatment with BML/PBS or BML/CTX increased the numbers of stem cells (C.Kit+Sca-1+) in BM; the effect of BML/CTX was higher, but with no significant effect on the numbers of HSCs. Future studies are needed to analyze the molecular components in BM lysate and to determine the underlying mechanisms.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Several studies have shown that different hematopoietic cells, including BM cells [ 17 ], platelets [ 18 ], and peripheral blood leukocytes [ 19 ] are rich in growth factors and cytokines. These factors have a great beneficial therapeutic potential in different disease settings.…”

Section: Introductionmentioning

confidence: 99%

Beneficial Modulatory Effects of Treatment With Bone Marrow Lysate on Hematopoietic Stem Cells and Myeloid Cells in Tumor-Bearing Mice

Salem¹,

El-Bakry²,

Moubark³

et al. 2022

Br J Biomed Sci

View full text Add to dashboard Cite

show abstract

“…Several reports have suggested that the beneficial effects of stem-based cell therapy are due to paracrine effects such as growth factors or cytokines from the cells, not due to the differentiation ability of the stem cells themselves [37]. In this regard, several studies have shown that different hematopoietic cells, including BM cells [17,25], platelets [18], and peripheral blood leukocytes [19] are rich in growth factors and cytokines, in particular insulin-like growth factor 1 (IGF-1) and vascular endothelial growth factor (VEGF). Given that these factors are of great beneficial therapeutic potential in different disease settings, the above-mentioned studies would indicate that BML may induce stem cell mobilization and the release of myeloid cells in particular in the leukopenic microenvironment [38].…”

Section: Discussionmentioning

confidence: 99%